On November 17, 2023, Robert L. Nussbaum, MD, Chief Medical Officer of Invitae Corporation (the ?Company?), notified the Company of his planned retirement, effective December 29, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0005 USD | -75.00% | -16.67% | -99.92% |
Apr. 25 | Labcorp beats quarterly estimates on strong testing demand | RE |
Apr. 25 | Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln | RE |
1st Jan change | Capi. | |
---|---|---|
-99.92% | 143K | |
-31.90% | 9.3B | |
-6.25% | 3.1B | |
-13.96% | 2.17B | |
-16.83% | 1.75B | |
+72.82% | 1.5B | |
+29.17% | 807M | |
-2.62% | 759M | |
-26.33% | 532M | |
+4.97% | 313M |
- Stock Market
- Equities
- NVTA.Q Stock
- News Invitae Corporation
- Invitae Corporation Announces the Retirement of Robert L. Nussbaum as Chief Medical Officer, Effective December 29, 2023